CA2373063A1 - Recepteur 4 contenant le domaine de la mort cellulaire programmee - Google Patents

Recepteur 4 contenant le domaine de la mort cellulaire programmee Download PDF

Info

Publication number
CA2373063A1
CA2373063A1 CA002373063A CA2373063A CA2373063A1 CA 2373063 A1 CA2373063 A1 CA 2373063A1 CA 002373063 A CA002373063 A CA 002373063A CA 2373063 A CA2373063 A CA 2373063A CA 2373063 A1 CA2373063 A1 CA 2373063A1
Authority
CA
Canada
Prior art keywords
polypeptide
antibody
amino acid
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373063A
Other languages
English (en)
Inventor
Jian Ni
Craig A. Rosen
James G. Pan
Reiner L. Gentz
Vishva M. Dixit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
University of Michigan
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373063A1 publication Critical patent/CA2373063A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention porte sur de nouvelles protéines du récepteur 4 (DR4) contenant le domaine de la mort cellulaire programmée et qui sont des éléments de la famille du récepteur du facteur de nécrose tumorale (TNF). L'invention porte notamment sur des molécules d'acide nucléique isolées codant les protéines humaines de DR4. L'invention porte également sur des polypeptides de DR4, ainsi que sur des vecteurs, des cellules hôtes et sur des procédés de recombinaison visant à produire ces polypeptides. L'invention porte en outre sur des procédés de criblage visant à identifier des agonistes et des antagonistes de l'activité de DR4 et sur des procédés d'utilisation des polynucléotides et polypeptides de DR4.
CA002373063A 1999-05-06 2000-05-05 Recepteur 4 contenant le domaine de la mort cellulaire programmee Abandoned CA2373063A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13292299P 1999-05-06 1999-05-06
US60/132,922 1999-05-06
PCT/US2000/012163 WO2000067793A1 (fr) 1999-05-06 2000-05-05 Recepteur 4 contenant le domaine de la mort cellulaire programmee

Publications (1)

Publication Number Publication Date
CA2373063A1 true CA2373063A1 (fr) 2000-11-16

Family

ID=22456184

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373063A Abandoned CA2373063A1 (fr) 1999-05-06 2000-05-05 Recepteur 4 contenant le domaine de la mort cellulaire programmee

Country Status (5)

Country Link
EP (1) EP1178828A4 (fr)
JP (1) JP2002544172A (fr)
AU (1) AU4984300A (fr)
CA (1) CA2373063A1 (fr)
WO (1) WO2000067793A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
WO1998032856A1 (fr) 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Recepteur 4 (dr4-recepteur 4 de mort cellulaire) contenant des domaines de mort cellulaire, membre de la superfamille du recepteur du facteur de necrose tumorale (tnf) et se liant a la queue (apo2-l)
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
JP3665316B2 (ja) * 2001-05-18 2005-06-29 麒麟麦酒株式会社 抗ｔｒａｉｌ−ｒ抗体
WO2002097033A2 (fr) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a des recepteurs de trail
WO2003013584A1 (fr) * 2001-08-09 2003-02-20 Genset S.A. Agonistes et antagonistes xafinix destines a etre utilises dans le traitement des troubles metaboliques
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
JP2008525002A (ja) * 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Ｂｃｍａポリペプチド及びその使用
WO2006083937A2 (fr) 2005-02-02 2006-08-10 The Uab Research Foundation Agents et methodes associes a la reduction de la resistance aux agonistes des recepteurs de mort induisant l'apoptose
EP2970473B1 (fr) 2013-03-14 2017-08-16 Bristol-Myers Squibb Company Combinaison d'agoniste de dr5 et d'antagoniste anti-pd-1 et méthodes d'utilisation associées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1998032856A1 (fr) * 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Recepteur 4 (dr4-recepteur 4 de mort cellulaire) contenant des domaines de mort cellulaire, membre de la superfamille du recepteur du facteur de necrose tumorale (tnf) et se liant a la queue (apo2-l)
WO1999002653A1 (fr) * 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Acide nucleique codant une nouvelle proteine induite par chimiotherapie, et ses procedes d'utilisation
WO1999037684A1 (fr) * 1998-01-26 1999-07-29 Genentech, Inc. Anticorps du recepteur 4 de la mort cellulaire (dr4) et leurs utilisations

Also Published As

Publication number Publication date
WO2000067793A9 (fr) 2002-04-18
WO2000067793A1 (fr) 2000-11-16
EP1178828A1 (fr) 2002-02-13
AU4984300A (en) 2000-11-21
JP2002544172A (ja) 2002-12-24
WO2000067793A8 (fr) 2001-05-25
EP1178828A4 (fr) 2004-10-13

Similar Documents

Publication Publication Date Title
US6433147B1 (en) Death domain containing receptor-4
US6455040B1 (en) Tumor necrosis factor receptor 5
US7186800B1 (en) Tumor necrosis factor 6α and 6β
US7452538B2 (en) Death domain containing receptor 4 antibodies and methods
US6743625B2 (en) Death domain containing receptor 5
US7476384B2 (en) Death domain containing receptor 4 antibody and methods
US7465707B2 (en) Methods of treatment with TR10 polypeptides
US7709218B2 (en) Tumor necrosis factor receptors 6α and 6β
US20060234285A1 (en) Tumor Necrosis Factor Receptors 6 Alpha & 6 Beta
US7357927B2 (en) Death domain containing receptors
US20030092101A1 (en) Human tumor necrosis factor receptors TR13 and TR14
CA2369371A1 (fr) Recepteur 5 contenant le domaine de l'apoptose
CA2373063A1 (fr) Recepteur 4 contenant le domaine de la mort cellulaire programmee
CA2371114A1 (fr) Recepteurs contenant un domaine de mort cellulaire
AU774845B2 (en) Tumor necrosis factor receptors 6alpha and 6beta
CA2374674A1 (fr) Recepteur 5 du facteur de necrose tumorale
EP1187842B1 (fr) Protéine de fusion entre Fc et TR10, RECEPTEUR DE FACTEUR DE NECROSE TUMORALE HUMAIN
US20020098163A1 (en) Human tumor necrosis factor receptors TR21 and TR22
CA2420593A1 (fr) Recepteurs du facteur de necrose tumorale 6$g(a) et 6$g(b)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead